NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$19.94 -0.05 (-0.25 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$19.51
Today's Range$19.42 - $20.03
52-Week Range$3.56 - $24.28
Volume9,550 shs
Average Volume429,709 shs
Market Capitalization$769.98 million
P/E RatioN/A
Dividend YieldN/A
Beta3.99
Rocket Pharmaceuticals logoRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, as well as a strategic research collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.

Receive RCKT News and Ratings via Email

Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RCKT
CUSIPN/A
Phone646-440-9100

Debt

Debt-to-Equity Ratio0.23
Current Ratio23.31
Quick Ratio23.31

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.02 per share
Price / Book2.84

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-29,490,000.00
Net MarginsN/A
Return on Equity-51.66%
Return on Assets-31.55%

Miscellaneous

Employees20
Outstanding Shares39,510,000
Market Cap$769.98

The Truth About Cryptocurrencies

Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) posted its quarterly earnings data on Friday, May, 11th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.14. View Rocket Pharmaceuticals' Earnings History.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Rocket Pharmaceuticals.

What price target have analysts set for RCKT?

3 analysts have issued twelve-month target prices for Rocket Pharmaceuticals' stock. Their forecasts range from $27.00 to $27.00. On average, they expect Rocket Pharmaceuticals' share price to reach $27.00 in the next year. This suggests a possible upside of 35.4% from the stock's current price. View Analyst Ratings for Rocket Pharmaceuticals.

What is the consensus analysts' recommendation for Rocket Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Rocket Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rocket Pharmaceuticals stock:
  • 1. William Blair analysts commented, "Rocket Pharmaceuticals, Inc. We are initiating coverage of Outperform rating and $32 fair value estimate. Rocket is a multi-platform biotechnology company that is focused on developing irst-in-class gene thera pies for rare dis- eases. The company’s lead candidate, RP-L102, is an ex vivo lentiviral gene therapy being developed for the treatment of Fanconi anemia (FA), with three additional ex vivo lentivirus programs in earlier development for the treatment of leukocyte adhesion deiciency-I (LAD-I), pyruvate kinase deiciency (PKD) , and infantile malignant osteopetrosis (IMO). We also expect the company to disclose its in vivo adeno-associated virus (AAV) gene therapy indication by year end, as the company anticipates having up to four programs in the clinic (likely and data from two (likely FA, LAD-I) in 2019. Plat- form and Longer Follow-Up." (7/10/2018)
  • 2. According to Zacks Investment Research, "Inotek Pharmaceuticals Corporation is a biopharmaceutical company. The company is focused on the discovery, development and commercialization of novel therapies to treat glaucoma and diseases of the eye. Inotek Pharmaceuticals Corporation is headquartered in Lexington, Massachusetts. " (9/12/2017)

Are investors shorting Rocket Pharmaceuticals?

Rocket Pharmaceuticals saw a increase in short interest in June. As of June 29th, there was short interest totalling 3,711,462 shares, an increase of 79.7% from the June 15th total of 2,065,369 shares. Based on an average trading volume of 659,648 shares, the days-to-cover ratio is presently 5.6 days. Currently, 10.0% of the shares of the stock are short sold. View Rocket Pharmaceuticals' Current Options Chain.

Who are some of Rocket Pharmaceuticals' key competitors?

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the folowing people:
  • Mr. Gaurav Shah, CEO & Pres
  • Mr. John C. Militello, Principal Financial & Accounting Officer and Controller (Age 45)
  • Ms. Kinnari Patel PharmD, MBA, Chief Operating Officer & Head of Devel.
  • Dr. Claudine Prowse Ph.D., Sr. VP Corp. Devel. & IRO
  • Mr. Jonathan Schwartz M.D., Chief Medical Officer and Head of Clinical Devel.

Has Rocket Pharmaceuticals been receiving favorable news coverage?

Headlines about RCKT stock have been trending somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Rocket Pharmaceuticals earned a coverage optimism score of 0.12 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.75 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.04%). View Institutional Ownership Trends for Rocket Pharmaceuticals.

Which major investors are buying Rocket Pharmaceuticals stock?

RCKT stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. View Insider Buying and Selling for Rocket Pharmaceuticals.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $19.94.

How big of a company is Rocket Pharmaceuticals?

Rocket Pharmaceuticals has a market capitalization of $769.98 million. Rocket Pharmaceuticals employs 20 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 430 EAST 29TH STREET SUITE 1040, NEW YORK NY, 10016. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]


MarketBeat Community Rating for Rocket Pharmaceuticals (NASDAQ RCKT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.